Mobile

Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open la...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002457-41

Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open label enoxaparin (Study no. 150-CL-008) Protocol for Phase 2B Study of YM150

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the optimal therapeutic dose by evaluation of the efficacy of YM150 in subjects undergoing elective primary hip replacement (HR) surgery. Evaluation of the safety of YM150 in the target population.

Critère d'inclusion

  • Elective primary hip replacement surgery

Liens